BrainStorm To Withdraw NurOwn BLA for Treatment of ALS

After an FDA advisory committee voted overwhelmingly against its ALS drug NurOwn, BrainStorm Cell Therapeutics announced that it is withdrawing the BLA for the drug so that it can conduct an additional phase 3 trial.
Source: Drug Industry Daily